SNTI News & Events

Reports Q4 revenue $22,000, consensus $500,000. "2025 was a year of important progress for Senti as we continued to advance our mission of developing next-generation cell and gene therapies powered by our synthetic biology platform. Over the past year, we have strengthened the clinical and translational foundation of our pipeline, with SENTI-202 as the lead program generating positive clinical data, while continuing to refine and expand the capabilities of our Gene Circuit platform. We remain focused on disciplined execution, advancing our key programs toward critical development milestones and positioning Senti to deliver smarter, more selective medicines for patients with serious diseases. I am proud of our team's commitment and believe the progress we made in 2025 positions us well for the opportunities ahead," commented Timothy Lu, co-founder and CEO of Senti Biosciences.

Senti Biosciences announced the completion of enrollment in its Phase 1 clinical trial evaluating SENTI-202, a first-in-class CD33/FLT3-targeting Logic Gated CAR NK cell therapy, in patients with relapsed or refractory acute myeloid leukemia. "The completion of enrollment in our Phase 1 trial represents a significant clinical milestone for our SENTI-202 program," said Kanya Rajangam, M.D., Ph.D. Chief Medical Officer at Senti Bio. "Importantly, the encouraging clinical data from this study provide a strong foundation as we actively design our pivotal program for SENTI-202 in AML, as well as potential indication expansion and later-stage clinical development. We look forward to having productive discussions and working closely with the FDA in the first half of this year to discuss the next phase of development for our RMAT-designated program."

Senti Biosciences announced that the U.S. Food and Drug Administration, FDA, has granted Regenerative Medicine Advanced Therapy, RMAT, designation to SENTI-202, the Company's potential first-in-class Logic Gated off-the-shelf chimeric antigen receptor natural killer, CAR-NK, investigational cell therapy, that is currently in development for the treatment of relapsed/refractory hematologic malignancies, including AML. "This significant FDA designation validates both the tremendous need for better treatments for R/R AML and the promise of SENTI-202 to transform the therapeutic landscape for this notoriously aggressive cancer," Timothy Lu, MD, PhD, Co-Founder and CEO of Senti Biosciences. "We are incredibly pleased with the exciting clinical progress we recently shared at the ASH conference on SENTI-202."